Novartis sales force reorganization
Executive Summary
As of Jan. 5, Novartis Pharmaceuticals is rolling out a nationwide restructuring of its U.S. sales forces. The new structure breaks up Novartis' nationwide, brand-centered sales forces into five primary care-focused regional operating units and one national specialty pharmaceutical business unit. Each unit will be led by a general manager. The reorganization sounds technical, but it is part of Novartis' major strategic shift to be more responsive to and devote more resources to new kinds of customers, such as payers and patient advocacy groups. As previously announced, about 550 sales rep positions are being cut as of that date
You may also be interested in...
Ending the Arms Race: Ten Priorities for Fixing the Commercial Model
Faced with growing budgets and declining effectiveness of commercial spending, most large companies have embarked on the next wave of significant commercial changes. But most of these efforts don't go far enough to address the rapid and fundamental changes in the stakeholder landscape which have knocked pharma dramatically out of alignment with its stakeholder base. The article describes ten priorities for drug companies to align their organizations with these new realities - including requirements for companies to partner with payors and providers in new ways, and make resource decisions much more selectively to focus on the stakeholders who really matter. Nonetheless, these changes won't have their full effect without a more fundamental rethinking of the industry's value proposition, taking into account not only product value, but the services and the customer experience offered to all stakeholders.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.